AD109, a new oral treatment for obstructive sleep apnea, significantly reduced AHI in a phase 3 trial, offering a non-device alternative for patients intolerant to CPAP. Over half of participants improved in disease severity, with strong safety and tolerability reported.
CardiologyPulmonology
< class="penci-entry-title entry-title grid-title penci_grid_title">Oral drug lowers OSA severity over 6 months